Cipla Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2025 • Pharmaceuticals: 95.3% • New Ventures: 4.7%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Company has a healthy return on capital (ROCE) of 20.8%
- Company has consistently been profitable over the last 5 years
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 0.98x)
- Company comfortably covers its interest (97.0x coverage)
- Company has a consistent dividend-paying track record
CONS
- Recent results are weak - TTM profit is down 33.0% versus prior year
- Total debt has risen sharply - up 180.1% year on year
- Recurring exceptional / one-off items are inflating headline profit
- Expensive relative to growth - PEG of 3.0
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| BIOCON | 390.95 | 128.63 | 63712.89 | 0.13 | 136.80 | 53.36 | 4336.00 | 10.89 | 3.26 | 19.54 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,269 | 6,589 | 6,506 | 6,082 | 6,625 | 6,961 | 6,962 | 6,598 | 6,837 | 7,447 | 6,963 | 6,464 | 7,119 | |
| 4,835 | 4,944 | 4,856 | 4,847 | 4,978 | 5,165 | 5,084 | 5,192 | 5,179 | 5,695 | 5,819 | 5,544 | 6,248 | |
| Operating Profit | 1,434 | 1,645 | 1,649 | 1,235 | 1,647 | 1,796 | 1,878 | 1,406 | 1,658 | 1,753 | 1,144 | 920 | 871 |
| OPM % | 22.88% | 24.96% | 25.35% | 20.30% | 24.86% | 25.80% | 26.97% | 21.30% | 24.25% | 23.53% | 16.42% | 14.23% | 12.23% |
| 136 | 176 | -10 | 249 | 160 | 191 | 222 | 289 | 259 | 269 | -70 | 148 | 211 | |
| Interest | 16 | 26 | 30 | 18 | 18 | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 17 |
| Depreciation | 239 | 290 | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 | 278 | 425 | 304 |
| Profit before Tax | 1,375 | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,080 |
| Tax % | 27.50% | 27.50% | 27.50% | 25.80% | 27.00% | 27.00% | 17.35% | 18.57% | 27.00% | 27.00% | 24.47% | 22.20% | 27.29% |
| Net Profit | 998 | 1,155 | 0 | 0 | 1,175 | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 |
| 12.34 | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 | 15.13 | 16.07 | 16.73 | 8.37 | 6.87 | 9.77 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 14,394 | 15,156 | 16,362 | 17,132 | 19,160 | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 | 27,994 | |
| 11,918 | 12,329 | 13,265 | 13,951 | 14,911 | 17,251 | 17,763 | 19,483 | 20,425 | 22,280 | 23,307 | |
| Operating Profit | 2,476 | 2,826 | 3,097 | 3,181 | 4,249 | 4,512 | 4,990 | 6,291 | 7,123 | 5,883 | 4,687 |
| OPM % | 17.20% | 18.65% | 18.93% | 18.57% | 22.18% | 20.73% | 21.93% | 24.41% | 25.86% | 20.89% | 16.74% |
| 229 | 280 | 477 | 369 | 270 | 140 | 330 | 552 | 867 | 606 | 558 | |
| Interest | 159 | 114 | 168 | 197 | 161 | 106 | 110 | 90 | 62 | 54 | 57 |
| Depreciation | 1,323 | 1,323 | 1,326 | 1,175 | 1,068 | 1,052 | 1,172 | 1,051 | 1,107 | 1,211 | 1,305 |
| Profit before Tax | 1,222 | 1,669 | 2,079 | 2,178 | 3,290 | 3,493 | 4,038 | 5,702 | 6,821 | 5,224 | 4,534 |
| Tax % | 14.71% | 14.98% | 27.39% | 28.98% | 27.01% | 26.73% | 29.79% | 27.12% | 22.43% | 25.92% | 25.82% |
| Net Profit | 1,042 | 1,419 | 1,510 | 1,547 | 2,401 | 2,559 | 2,835 | 4,155 | 5,291 | 3,870 | 3,363 |
| EPS | 12.50 | 17.50 | 18.93 | 19.16 | 29.79 | 31.17 | 34.69 | 51.05 | 65.29 | 48.02 | — |
| Dividend Payout % | 15.99% | 17.12% | 15.82% | 20.85% | 16.77% | 16.03% | 24.49% | 25.47% | 24.51% | 27.07% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 8%
- 5 Years:
- 8%
- 3 Years:
- 7%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 11%
- 5 Years:
- 10%
- 3 Years:
- 11%
STOCK PRICE CAGR
- 10 Years:
- 9%
- 5 Years:
- 8%
- 3 Years:
- 3%
- 1 Year:
- -12%
RETURN ON EQUITY
- 10 Years:
- 13%
- 5 Years:
- 15%
- 3 Years:
- 16%
- Last Year:
- 12%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 | 162 |
| Minority Interest | 438 | 352 | 332 | 294 | 259 | 276 | 306 | 96 | 96 | 88 |
| 12,321 | 14,002 | 14,794 | 15,549 | 18,123 | 20,636 | 23,185 | 26,458 | 30,918 | 34,208 | |
| 4,251 | 4,241 | 4,787 | 3,161 | 1,897 | 1,120 | 563 | 603 | 493 | 792 | |
| Trade Payables | 1,571 | 2,119 | 1,948 | 2,282 | 2,067 | 2,508 | 2,535 | 2,474 | 2,837 | 3,230 |
| 2,127 | 1,797 | 1,740 | 1,976 | 2,330 | 1,951 | 2,258 | 2,337 | 2,237 | 3,116 | |
| Total Liabilities | 20,869 | 22,673 | 23,762 | 23,423 | 24,837 | 26,652 | 29,007 | 32,130 | 36,742 | 41,595 |
| 9,490 | 9,949 | 9,547 | 9,559 | 9,394 | 9,622 | 9,101 | 9,494 | 9,895 | 12,434 | |
| Capital Work in Progress | 719 | 512 | 331 | 421 | 571 | 383 | 689 | 864 | 1,213 | 1,586 |
| 973 | 1,259 | 2,554 | 1,471 | 2,710 | 2,551 | 3,662 | 5,449 | 7,933 | 8,223 | |
| 3,485 | 4,045 | 3,965 | 4,378 | 4,669 | 5,350 | 5,156 | 5,238 | 5,642 | 6,597 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,771 | 5,506 | 5,620 | |
| Cash & Bank | 624 | 966 | 619 | 1,004 | 1,401 | 1,928 | 1,565 | 875 | 800 | 1,307 |
| 5,577 | 5,942 | 6,747 | 6,591 | 6,092 | 6,818 | 8,833 | 5,439 | 5,753 | 5,827 | |
| Total Assets | 20,869 | 22,673 | 23,762 | 23,423 | 24,837 | 26,652 | 29,007 | 32,130 | 36,742 | 41,595 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2,832 | 2,185 | 2,284 | 3,917 | 4,793 | 4,465 | 4,540 | 4,134 | 5,005 | 3,940 | |
| Cash from Investing | -1,310 | -854 | -1,669 | 104 | -2,387 | -1,872 | -2,389 | -2,988 | -3,691 | -2,326 |
| Cash from Financing | -1,326 | -385 | -349 | -2,949 | -1,240 | -1,600 | -958 | -1,200 | -1,293 | -1,234 |
| -254 | 223 | -326 | 224 | 129 | -146 | -109 | -55 | 21 | 380 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-03 - Cipla Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US".
2026-09-03 - Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company.
2026-09-02 - Cipla Limited has informed the Exchange about Newspaper Publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares
2026-08-31 - Cipla Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)".
2026-08-28 - Cipla Limited has informed the Exchange about Update on USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
2026-08-27 - Cipla Limited has informed the Exchange about Other Restructuring
2026-08-27 - Cipla Limited has informed the Exchange about Schedule of meet
2026-08-26 - Cipla Limited has informed the Exchange regarding Allotment of 5281 Shares.
2026-08-25 - Cipla Limited has informed the Exchange about USFDA inspection at Company s manufacturing facility in Pithampur, India
News
Recent coverage and analyst commentary for CIPLA
Loading news…
AI Stock Analyst
Cipla Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account